REG - Immupharma PLC - COLLABORATION WITH IMPERIAL COLLEGE LONDON

ImmuPharmaAnnouncement

29/11/2021 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20211129:nRSc7976Ta&default-theme=true

RNS Number : 7976T  Immupharma PLC  29 November 2021

 

 

RNS | 29 NOVEMBER 2021

ImmuPharma PLC

("ImmuPharma" or the "Company")

COLLABORATION WITH IMPERIAL COLLEGE LONDON

 

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development
company,

is very pleased to announce that it has signed a 2-year collaboration
agreement with Imperial College London.

 

Under the collaboration, Imperial College will provide significant
intellectual input and guidance on a number of innovative peptide assets
being developed at our R&D subsidiary, ImmuPharma Biotech in Bordeaux.

 

Dr Tim Franklin, Chief Operating Officer of ImmuPharma, added: "We are all
extremely excited to be working with such a world leading academic institute.
This union will be invaluable in guiding and progressing our earlier stage
product development portfolio, as well as enhancing our intellectual property
base."

 

Dr Sébastien Goudreau, Chief Executive Officer of ImmuPharma Biotech, added:
"We are delighted that now with the full support from the new Board for our
innovative research programs, we have the opportunity of working with
collaboration partners which include world leading academic institutes such as
Imperial College London."

 

End

 

 

This announcement contains inside information as stipulated under the UK
version of the Market Abuse Regulation no 596/2014 which is part of English
law by virtue of the European (withdrawal) Act 2018, as amended.  On
publication of this announcement via a regulatory information service, this
information is considered to be in the public domain.

 

 

 

 For further information please contact:

ImmuPharma PLC (www.immupharma.com (http://www.immupharma.com) )        + 44 (0) 207 152 4080

 Tim McCarthy, Chairman and Chief Executive Officer
 Dr Tim Franklin, Chief Operating Officer
 Lisa Baderoon, Head of Investor Relations & Non-Executive Director      + 44 (0) 7721 413496

 SPARK Advisory Partners Limited (NOMAD)                                 +44 (0) 203 368 3550

 Neil Baldwin

 Stanford Capital Partners (Joint Broker)                                +44 (0) 20 3650 3650

 Patrick Claridge

 John Howes

 Bob Pountney

 SI Capital (Joint Broker)                                               +44 (0) 1483 413500

 Nick Emerson

 

 

 

Notes to Editors

 

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that
discovers and develops peptide-based therapeutics. The Company's portfolio
includes novel peptide therapeutics for autoimmune diseases, metabolic
diseases, anti-infectives and cancer. The lead program, Lupuzor™, is a
first-in class autophagy immunomodulator which is in Phase 3 for the treatment
of lupus and preclinical analysis suggest therapeutic activity for many other
autoimmune diseases that share the same autophagy mechanism of action.
ImmuPharma and Avion Pharmaceuticals signed on 28 November 2019, an exclusive
licence and development agreement and trademark agreement for Lupuzor™ to
fund a new international Phase 3 trial for Lupuzor™ and commercialise in the
US. The Lupzor™ Phase 3 trial is on track to commence in 2022.

 

For additional information about ImmuPharma please visit
www.immupharma.co.uk

 

ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895.

 

About Imperial College London

Imperial College is a global top ten university with a world-class reputation
in science, engineering, business and medicine. For more information go to:
https://www.imperial.ac.uk (https://www.imperial.ac.uk)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCMZMZMVNFGMZM